The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2026

Filed:

Sep. 12, 2025
Applicants:

Sionna Therapeutics Inc., Waltham, MA (US);

Genzyme Corporation, Cambridge, MA (US);

Inventors:

Junkai Liao, Andover, MA (US);

John E. Macor, Washington Crossing, PA (US);

George Topalov, Pittsburgh, PA (US);

Mark Munson, Acton, MA (US);

Sukanthini Thurairatnam, Dover, MA (US);

Bradford Hirth, Littleton, MA (US);

Zhongli Gao, Waltham, MA (US);

Gregory Donald Hurlbut, Boxborough, MA (US);

Andrew Good, Bideford, GB;

Roy Vaz, Southborough, MA (US);

Jinyu Liu, Union City, CA (US);

Yi Li, Weston, MA (US);

Anatoly Ruvinsky, Lexington, MA (US);

Michael Kothe, Medway, MA (US);

David Borcherding, Bangor, PA (US);

Patrick Bernardelli, Paris, FR;

Arielle Genevois Borella, Paris, FR;

Franck Caussanel, Paris, FR;

Ingrid Devillers, Paris, FR;

Eric Nicolai, Paris, FR;

Franck Slowinski, Paris, FR;

Fabienne Thompson, Paris, FR;

Lothar Schwink, Frankfurt am Main, DE;

Heiner Glombik, Frankfurt am Main, DE;

Stefan Guessregen, Frankfurt am Main, DE;

Michael Podeschwa, Frankfurt am Main, DE;

Nils Rackelmann, Frankfurt am Main, DE;

Sven Ruf, Frankfurt am Main, DE;

Assignees:

Genzyme Corporation, Cambridge, MA (US);

Sionna Therapeutics Inc., Waltham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 515/18 (2006.01); A61K 31/4162 (2006.01); A61K 31/4188 (2006.01); A61K 31/4192 (2006.01); A61K 31/4196 (2006.01); A61K 31/422 (2006.01); A61K 31/424 (2006.01); A61K 31/429 (2006.01); A61K 31/433 (2006.01); A61K 31/439 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/504 (2006.01); A61K 31/5377 (2006.01); A61P 11/12 (2006.01); C07D 513/22 (2006.01); C07D 515/22 (2006.01);
U.S. Cl.
CPC ...
C07D 515/18 (2013.01); A61K 31/4162 (2013.01); A61K 31/4188 (2013.01); A61K 31/4192 (2013.01); A61K 31/4196 (2013.01); A61K 31/422 (2013.01); A61K 31/424 (2013.01); A61K 31/429 (2013.01); A61K 31/433 (2013.01); A61K 31/439 (2013.01); A61K 31/4439 (2013.01); A61K 31/444 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/504 (2013.01); A61K 31/5377 (2013.01); A61P 11/12 (2018.01); C07D 513/22 (2013.01);
Abstract

The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.


Find Patent Forward Citations

Loading…